Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
DivvyHQ landed Novel’s first investment by avoiding hockey-stick growth, co-founder says
It was a marriage of the minds, said DivvyHQ co-founder Brody Dorland, describing his marketing tech firm’s recent investment from Novel Growth Partners. The company’s leadership — Dorland and co-founder Brock Stechman — is honored to be recipients of NGP’s first investment, Dorland said. But the pairing didn’t come by accident, he added. “I think they viewed…
In talent showdown with corporate neighbors, startups must hire smarter, say Digital Sandbox experts
Kansas City heavy-weights like Garmin and Cerner court developers at the student level, said Brody Dorland, discussing a talent showdown seen by startups across the metro. “How am I supposed to compete with that?” asked Dorland, co-founder of marketing tech firm DivvyHQ, during a recent Digital Sandbox: Summer in the Sand panel about growing startup…
KC Fed: Want to strengthen Kansas City’s job market? Narrow skills gap caused by digital division
Digital division in Kansas City is taking its toll on the local workforce, said Jeremy Hegle. More must be done to allow skilled workers access to technology — in turn offering them a chance to succeed in a rapidly growing electronic economy, added Hegle, Federal Reserve Bank of Kansas City senior community development advisor. In…
Vote now: Kansas Citians vie to lead tech, education panels at SXSW 2019
A cadre of Kansas Citians are hoping to take the podium at one of the nation’s largest tech and innovation conferences in 2019. At least four Kansas City tech and entrepreneurship leaders are vying for panel or speaking spots at the 2019 South by Southwest conference March 8-17 in Austin, Texas. SXSW recently opened voting…